

Electronic Supporting Information for:

Tuning the composition of biocompatible Gd nanohydrogels to achieve hypersensitive dual T_1/T_2 MRI contrast agents

Dr. M. Callewaert et al.

Table of Contents

ESI-1. Evolution of T_1 relaxation rates (40 MHz, 37°C) for a- GdDOTP (2×10^{-3} M) and b- MS325 (2×10^{-3} M) in citric acid solution (10% v/v). T_1 relaxation rates of GdCl₃ (2×10^{-3} M) in citric acid solution are given for comparison.

ESI-2. Size distribution of a- GdDOTP⊂NP2 and b- MS325⊂NP2 from AFM images.

ESI-3. Speciation diagrams of GdDOTP, GdDOTA as a function of pH.

ESI-4. Release profiles at 37 °C of MS325⊂NP2 in a- phosphate buffer, b- simulated plasma


ESI-5. Relaxivity calculations

ESI-6. Comparison of GdDOTP⊂NP1 and GdDOTA⊂NP1 NMRD relaxivity profiles


ESI-7. a- T_1 -weighted images of 1) DOTAREM® and 2) Na₅GdDOTP as controls 3) GdDOTP⊂NP1 – protocol 1, b- T_2 -weighted images for the same solutions as in a). Samples imaged at 3 T, 37°C, and standard spin echo (SE) sequence.

ESI-8. Percentage of primary fibroblast cells survival a- in presence of unloaded NPs and b- in presence of Gd⊂NPs, as a function of increasing concentrations. Results obtained after 48 h of incubation.





a)



b)




ESI-1. Evolution of T_1 relaxation rates for a- GdDOTP (■: $1.5 \times 10^{-3} \text{M}$) and b- MS325 (●: $4 \times 10^{-3} \text{M}$) in citric acid solution (10% v/v). T_1 relaxation rates of GdCl₃ (□) in citric acid solution are given for comparison (concentrations identical to the ones of GdDOTP or MS325 respectively).




ESI-2. Size distribution of a- GdDOTP-NP2 and b- MS325-NP2 from AFM images

a)




b)



ESI-3. Speciation diagrams of a- GdDOTP^a, b- GdDOTA^b as a function of pH

References:

- a. A. D. Sherry, J. Ren, J. Huskens, E. Brucher, E. Toth, C. F. C. G. Geraldes, M. M. C. A. Castro and W. P. Cacheris, *Inorg. Chem.*, 1996, **35**, 4604.
- b. E. T. Clarke and A. E. Martell, *Inorg. Chim. Acta*, 1999, **190**, 37.



ESI-4. Release profiles at 37 °C of MS325-NP2 in a- phosphate buffer, b- simulated plasma

ESI-5. Relaxivity calculations

The reported relaxivities corresponded to the contribution of Gd centers buried inside the nanoparticles. To obtain these values:

- T_1 (and T_2) relaxation times of GdNPs were measured.
- $1/T_{1\text{para}}$ (and $1/T_{2\text{para}}$) values were calculated and the diamagnetic contribution was subtracted to these values (the diamagnetic contribution being obtained by measurements T_1 and T_2 relaxation times of unloaded NP). This gives $R_{1\text{para}}$ (and $R_{2\text{para}}$) relaxation rates for the nanosuspensions. The values obtained at 20 MHz and 37°C for nanosuspensions given in Table 2 are the following:

	[Gd] _{NPs} mM	[Gd] _{free} mM	$R_{1\text{para}}$	$R_{2\text{para}}$
GdDOTP⊂NP1	0.397	0.022	16.57	19.01
GdDOTP⊂NP2	0.14	0.07	14.01	15.64
MS325⊂NP2	1.745	1.274	99.93	114.95

For each nanosuspension, the amount of Gd entrapped in the nanoparticles and the amount that remains free in the nanosuspension (or at least weakly bound to the nanoparticles) were systematically determined (details given in the experimental section – determination of the Gd loading by ICP OES). Therefore, to obtain r_1 values associated to GdNPs, the contribution of free chelates present in the nanosuspension must be removed according to:

$$r_1(\text{GdCA} \subset \text{NP}) = (R_{1\text{para}} - ([\text{Gd}]_{\text{free}} * r_1(\text{GdCA}_{\text{free}})) / [\text{Gd}]_{\text{NPs}} \text{ (mM}^{-1} \text{ s}^{-1}) \text{ that gives:}$$

$$r_1(\text{GdDOTP} \subset \text{NP1}) = (16.57 - (0.022 * 4.2)) / 0.397 = 41.5 \text{ mM}^{-1} \text{ s}^{-1}$$

$$r_1(\text{GdDOTP} \subset \text{NP2}) = (14.01 - (0.07 * 4.2)) / 0.14 = 97.97 \sim 98 \text{ mM}^{-1} \text{ s}^{-1}$$


$$r_1(\text{MS325} \subset \text{NP2}) = (99.93 - (1.274 * 5.9)) / 1.745 = 52.9 \text{ mM}^{-1} \text{ s}^{-1}$$

$$\text{with } r_1(\text{GdDOTP}) = 4.2 \text{ mM}^{-1} \text{ s}^{-1} \text{ and } r_1(\text{MS325}) = 5.9 \text{ mM}^{-1} \text{ s}^{-1}$$


Similar calculations were done for r_2 values in Table 2. Similar treatments were applied to the NMRD profiles given in Figure 3.

For each nanosuspension the contribution of free chelates to the overall relaxivity (20MHz, 37°C) is given in the following table:



	[Gd] _{free} mM	$R_{1\text{para}}$	$R_{1\text{para}}(\text{Gd}_{\text{free}}) / R_{1\text{para}}$
GdDOTP⊂NP1	0.022	16.57	$(0.022 * 4.2) / 16.57 = 0.56\%$
GdDOTP⊂NP2	0.07	14.01	$(0.07 * 4.2) / 14.01 = 2.1\%$
MS325⊂NP2	1.274	99.93	$(1.274 * 5.9) / 99.93 = 7.5\%$



ESI-6. Comparison of GdDOTP_cNP1 and GdDOTA_cNP1 NMRD relaxivity profiles



ESI-7. a- T_1 -weighted images of 1) GdDOTP \subset NPs – protocol 1, 2) Na₅GdDOTP and 3) DOTAREM[®] as controls. b- T_2 -weighted images for the same solutions as in a). Samples imaged at 3 T, 37°C, and standard spin echo (SE) sequence.



ESI-8. Percentage of primary fibroblast cells survival a- in presence of unloaded NPs and b- in presence of Gd \subset NPs, as a function of increasing concentrations. Results obtained after 48 h of incubation.